Low dose methotrexate enhances lymphocytic JAM-A expression in rheumatoid arthritis
International Immunopharmacology · 2026-12 · 190 · 117464
DOI: 10.1016/j.intimp.2026.117464 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von Daniel H Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Daniel H. Park; Han Yu; Haoling Song, Lei Ding: School of Life Sciences, Yunnan University, Kunming, Yunnan 650500, China; Daniel H. Park: School of …. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Cell Adhesion Molecules, Lymphocytes. Die Arbeit nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVES: Endothelial Junction Adhesion Molecule A (JAM-A) functionally manages immune cell infiltration via tight junctions during the pathological development of human immune diseases. However, the expression and function of JAM-A on peripheral lymphocytes are yet to be well understood. The current study aims to identify the expression and functional roles of JAM-A on peripheral lymphocyte in the context of RA treated with low-dose methotrexate (MTX). METHODS: The proportion of JAM-A+ cells in RA patients and healthy controls were detected by flow cytometry (FCM). Functional validation and the regulatory mechanism between JAM-A and integrin β1 inperipheral lymphocytes were evaluated using quantitative real-time polymerase chain reaction (RT-qPCR), bisulfite sequencing PCR (BSP-PCR), the cell adhesion assay, and MTX treatment in vitro. RESULTS: In this study, we report that JAM-A mediates lymphocytic cellular adhesion to the extracellular matrix (ECM). Knockdown of JAM-A genes or blocking cell surface JAM-A protein dimerization decreases lymphocyte adhesion to the ECM. Consistently, over-expressing JAM-A enhances lymphocytic ECM adhesion by increasing downstream adhesive proteins, namely integrin β1. In rheumatoid arthritis (RA), we found that increased proportion of JAM-A+ cells are associated with low dose MTX clinical treatments. Furthermore, treating lymphocytes with 0.01 μg/ml MTX in vitro elevates JAM-A expression by inhibiting methylation level of CpG islands in the JAM-A promotor region. In addition, we noticed that an increased level of JAM-A expression induced by low dose MTX does not directly counteract MTX's inhibitory effects on cell-to-ECM adhesion. CONCLUSION: Regardless, our findings suggest that JAM-A-mediated adhesion of lymphocytes potentially plays an important role during pathogenesis and clinical low dose MTX treatments of RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Daniel H. Park; Han Yu; Haoling Song, Lei Ding: School of Life Sciences, Yunnan University, Kunming, Yunnan 650500, China; Daniel H. Park: School of Medicine, The University of Kansas Medical Center, Kansas City, Kansas…
- Daniel H. Park; Han Yu; Haoling Song, Lei Ding: School of Life Sciences, Yunnan University, Kunming, Yunnan 650500, China.
- Daniel H. Park; Han Yu; Haoling Song, Lei Ding: School of Life Sciences, Yunnan University, Kunming, Yunnan 650500, China. Electronic address: dingleiynu@ynu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Park, D. H., Yu, H., Song, H., & Ding, L. (2026). Low dose methotrexate enhances lymphocytic JAM-A expression in rheumatoid arthritis. International Immunopharmacology, 190, 117464. https://doi.org/10.1016/j.intimp.2026.117464
Vancouver
Park DH, Yu H, Song H, Ding L. Low dose methotrexate enhances lymphocytic JAM-A expression in rheumatoid arthritis. International Immunopharmacology. 2026;190:117464. doi:10.1016/j.intimp.2026.117464
BibTeX
@article{Park2026,
author = {Park, Daniel H and Yu, Han and Song, Haoling and Ding, Lei},
title = {Low dose methotrexate enhances lymphocytic JAM-A expression in rheumatoid arthritis},
journal = {International Immunopharmacology},
year = {2026},
volume = {190},
pages = {117464},
doi = {10.1016/j.intimp.2026.117464}
}
EUVIMED